Highlights

  • NAN shares closed at $3.68, up 1.38% on 24 August 2026
  • Investors notified on 7 August 2026 about the full-year results webinar
  • Core Business is infection-prevention technology, led by the trophon ultrasound-probe disinfection system
  • Continuing to expand its international installed base and develop new applications

Nanosonics Ltd (ASX:NAN) shares closed at $3.68, up 1.38% on 24 August 2026. The stock remains on investor radars as the infection-prevention technology company approaches its FY2026 full-year results webinar, with its trophon disinfection system continuing to expand internationally.

About Nanosonics Ltd

Nanosonics Ltd is an Australian healthcare technology company specialising in infection-prevention solutions, best known for its trophon ultrasound-probe disinfection system used widely across hospitals and clinics globally. The trophon system is designed to provide high-level disinfection of ultrasound probes between patient uses, addressing an important infection-control requirement within modern healthcare settings. Nanosonics has built its commercial model around both the Placement of trophon devices and the ongoing sale of consumables required for the system's operation, creating a Recurring Revenue stream that complements the upfront device-installation revenue. The company has pursued international expansion over an extended period, growing its installed base of devices across multiple healthcare markets, while also investing in the development of new products and applications that build on its core expertise in infection-prevention technology. As global healthcare systems continue to place growing emphasis on infection control and prevention standards, Nanosonics has positioned itself as a specialist provider addressing this critical area of clinical practice.

Key Developments

Nanosonics is approaching its FY2026 financial-results update, with the company notifying investors on 7 August 2026 about its full-year results webinar, an event that will provide detailed commentary on the company's recent performance and strategic direction. The company's core business remains infection-prevention technology, led by the trophon ultrasound-probe disinfection system, which continues to serve as the primary driver of both device placements and recurring consumables revenue. Nanosonics continues to expand its international installed base while developing new products and applications around healthcare infection prevention, reflecting the company's ongoing efforts to broaden its addressable market beyond its established trophon franchise. Investors are watching sales growth, recurring consumables revenue and adoption of trophon across hospitals and clinics, as these metrics provide important insight into both the near-term commercial performance and the long-term durability of the company's recurring revenue model. The FY2026 results should provide the clearest update yet on commercial momentum, international expansion and progress toward broadening Nanosonics's technology platform, with management commentary at the upcoming webinar likely to shed further light on the company's priorities for the year ahead.

Conclusion

With its FY2026 full-year results webinar approaching, Nanosonics is set to provide investors with important updates on the ongoing performance of its trophon disinfection system and broader infection-prevention platform. Continued growth in international device placements and recurring consumables revenue remains central to the company's Investment case. Investors will be watching closely for evidence that Nanosonics can sustain its commercial momentum while successfully expanding its technology platform beyond its core trophon business.